UTHR News and Press, United Therapeutics Corporation From 12/20/23

2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...

2023-12-20 09:54:22 ET More on Liquidia Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript Liquidia prices equity offering Liquidia gains as court sets December date for hearing in patent dispute Seeking Alpha’s Quant Rating on Liquidia ...

2023-12-18 12:05:08 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Be Cautious Of High Valuations Top stocks with earning stability and quality + overweight - MS Morgan Stanley: Dividend paying stocks > non-dividend paying stocks, since 2000 Seeking ...

United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“ Merger Sub ”), has successfully completed the previously announced tender...

United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“ Merger Sub ”), a wholly owned subsidiary of United Therapeutics, to acquire all...

2023-12-10 10:41:03 ET Summary Today, we take a deeper look at United Therapeutics Corporation, whose shares are cheap but the company does have litigation concerns. The company's treprostinil products are also facing challenges from generics and clinical aspirants, and its growth...

United Therapeutics (Nasdaq: UTHR ), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024 . This award is presented by Newsweek and Statista Inc., the world-leading statistics po...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...

2023-11-25 03:20:10 ET Summary Latest revenue results are not favorable for MannKind nor United. MannKind needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. United has been an unreliable partner for future use of MannKind's technology...